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Abstract  
 
Introduction: Incidental liver irradiation during breast radiotherapy can increase the risk of 
second primary malignancy and induce adverse inflammatory states. This study establishes 
the volume of liver irradiated during free-breathing breast radiotherapy. Novel associations 
between liver dose-volume data and systemic interleukin-6 soluble receptor and blood 
counts are evaluated. 
Methods: The volume of liver within the 10%, 50% and 90% isodose was determined for 100 
women with stage 0 to II breast carcinoma undergoing 40Gy in 15 fractions over three weeks 
tangential irradiation. Blood counts and interleukin 6 soluble receptor concentration were 
recorded before, during and four weeks after radiotherapy. Dose-volume data for right-sided 
treatments was associated with longitudinal measures at bivariate and multivariable levels. 
Results:  
A maximum of 226cm3 (19%), 92cm3 (8%) and 62cm3 (5%) of the liver was irradiated within 
the 10%, 50% and 90% isodose. Liver irradiation was almost exclusively a feature of the 52 
right-sided treatments and was strongly correlated with breast volume (ρ = .7, p<0.0001). 
Liver V10% was significantly associated with interleukin-6 soluble receptor concentration 
four weeks post-radiotherapy (beta = 0.38, p = 0.01) after controlling for theoretical 
confounding variables.  
Conclusion: Up to 8% of the liver is irradiated within the primary beam during local right-
sided breast radiotherapy. Select use of a deep inspiration breath hold technique would 
reduce this volume, and minimise the risk of radiation-induced malignancy and acute 
systemic elevation of inflammatory interleukin 6 soluble receptor. 
Key words: Breast radiotherapy; right-sided; liver irradiation; deep inspiration breath hold; 
soluble interleukin 6 receptor 
 
Highlights 
 A portion of the liver is irradiated for some patients during free breathing breast 
radiotherapy 
 The likelihood of liver irradiation increases with breast size/volume 
 Low dose to a larger volume of liver associated with a systemic inflammatory mediator 
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Background  
Radiotherapy after breast conserving surgery halves the risk of carcinoma recurrence at 10 
years.1 Eight-out-of ten women treated are expected to be alive at that point,2 so related 
morbidity assumes greater significance. Toxicity from incidental heart irradiation3 has led to 
widespread adoption of deep inspiration breath-hold (DIBH) techniques for patients with 
left-sided breast tumours, which reduce cardiac doses by around 50%.4  
The latency and incidence of a cardiac event are comparable to that for a second primary 
cancer (SPC) after breast radiotherapy.5 Low dose to structures at the target periphery are 
thought to contribute to SPC incidence.6 Depending upon patient anatomy and treatment 
technique, a superior portion of the liver lies within the irradiated volume during right-sided 
treatment: an effect enhanced by the rise of abdominal organs with arms abducted above 
the head. An in-silico study estimated liver irradiation in this setting confers a significant 
lifetime SPC risk, albeit much lower than for the lung.7 The relevance of low-dose exposure 
to a liver volume has not been evaluated using real patient dosimetry.8 
Very limited published evidence from four patients reports that between 4 and 31.5cm3 of 
the liver is irradiated within the 50% isodose during free-breathing radiotherapy breast 
tangents,9 with a further single case citing 134cm3.10 Our separate pilot study, of eight right-
sided and six left-sided local breast targets, confirmed that up to 5%, mean 1.9%, of the liver 
was irradiated within the primary beam.11 
Acute radiation damage to hepatic cells ranges from asymptomatic elevated liver function 
tests12 and radiologically-detected focal parenchyma damage13 to a significant veno-
occlusive pathology late in the acute period encompassing liver inflammation, steatosis, 
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fibrosis and necrosis.14,15 Chemotherapy, volume irradiated and dose-per fraction all 
modulate the risk of liver toxicity.16 
This study characterises the volume of incidental liver irradiation during free-breathing 
breast radiotherapy. The clinical implications for our participants, who received hypo-
fractionated treatment with no prior chemotherapy, are evaluated with reference to novel 
associations between liver dose and systemic sIL-6R (a mediator of hepatic 
inflammation17,18) and blood counts. 
Methods  
A pragmatic sample size of 100 women with stage 0 to II breast carcinoma were 
prospectively recruited from new patient clinics at a major regional cancer centre. All had 
undergone breast conserving surgery or mastectomy and 40Gy in 15 fractions over three 
weeks adjuvant radiotherapy prescribed (± tumour bed boost). Patients who had received 
prior systemic anti-cancer therapy were excluded to enable a direct evaluation of radiation 
effects. Endocrine therapy was scheduled after radiotherapy. Uncontrolled heart, lung, 
thyroid and liver disease or pre-existing chronic fatigue, autoimmune or inflammatory 
disease excluded 15 potential participants. The study protocol was approved by NHS Ethics 
Committee 07/WSE04/82. 
Radiotherapy planning data 
A breast clinical target volume (CTV), comprising all subcutaneous tissue to the pectoral 
fascia, was defined during free breathing CT. An expansion margin excluding the most 
superficial 5mm formed a planning target volume (PTV). Chestwall CTV extended from skin 
to rib-pleural margin. Tangential fields created a non-divergent posterior border and the 
beam arrangement optimised to achieve a maximum lung and heart field projection of 
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≤20mm and ≤15mm, respectively. Wedges were applied with the goal of achieving PTV dose 
homogeneity between 95% and 107% of reference dose. Beam energy was 6MV unless a 
tangential separation of >20cm meant 10MV improved dose homogeneity. The couch was 
rotated to remove divergence from the tangential field superior margin if supraclavicular 
fossa (SCF) irradiation was indicated. 
A researcher contoured the liver extent on contiguous 3mm slices. Gall bladder and extra-
parenchymal inferior vena cava and portal vein were excluded. An experienced radiologist 
prospectively checked the structure delineation on the first five cases and a random 
retrospective sample of a further five plans. A collapsed cone algorithm [Oncentra 
Masterplan v4.1] with 3mm voxel size calculated the dose distribution.  
Longitudinal data 
Circulating blood counts and sIL-6R concentration were observed at baseline (between 10 
and 22 days before radiotherapy), after 10 and 15 fractions and four weeks after 
radiotherapy. Enzyme-linked immunosorbent assay quantified sIL-6R serum concentration 
[R&D Systems]. Full blood counts were auto-analysed [Pentra XL 80]. Potential confounding 
variables depression and physical activity were self-reported via the hospital anxiety and 
depression scale (HADS) and international physical activity questionnaire (IPAQ), 
respectively and body mass index (BMI) was recorded. 
Data analysis 
Descriptive statistics included the absolute (cm3) and relative (%) volume of liver irradiated 
to at least 10, 50 and 90% of the prescription dose (Vliver10,50,90), and maximum, mean 
(standard deviation) and median (interquartile range) liver doses. When the full extent of 
liver was not included in the scan, the volume of liver was imputed based on the weight of 
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the participant.19 The volume of external contour irradiated within the 95% isodose 
(Vbreast95) was chosen as a breast size proxy. 
Bivariate correlations were conducted between the liver dose-volume data and breast 
volume, longitudinal sIL-6R concentration and 12 blood count parameters. Non-parametric 
statistics were used where data did not fulfil assumptions underlying parametric tests. The 
relative contribution of liver dose-volume parameters to variance in sIL-6R was evaluated 
using multiple regression. Significance level was reduced to p < 0.01 to adjust for multiple 
testing. 
 
Results  
Forty-eight of the 100 participants had a left-sided tumour and 52 were right-sided (Table 
1).  
Table 1 Characteristics of participants, presented as means (SD) or number (%) 
Characteristic Left-sided 
(n = 48) 
Right-sided 
(n = 52) 
Age (years) 58.5. (9.3) 57.9 (8.1) 
BMI (Kg/m2) 28.1 (4.5) 28.2 (4.9) 
Smoking history (pack years) 10.5 (14.2) 6.9 (11.5) 
HADS anxiety score 
HADS depression score 
5.1 (3.0) 
3 (3.2) 
6 (3.9) 
3 (2.8) 
IPAQ score (MET-min/week) 2446 (2447) 2170 (1880) 
HRT history 
    never 
    previous 
 
36 (75%) 
12 (25%) 
 
34 (66%) 
18 (34%) 
Histological diagnosis 
    ductal carcinoma in-situ 
    invasive ductal carcinoma 
    other     
 
5 (10%) 
33 (69%) 
10 (21%) 
 
8 (15%) 
34 (66%) 
10 (19%) 
TNM stage  
    0 
    I 
    II 
 
5 (10%) 
30 (63%) 
13 (27%) 
 
8 (15%) 
40 (77%) 
4 (8%) 
Histopathological grade   
7 
 
    1  
    2 
    3 
9 (19%) 
33 (68%) 
6 (13%) 
22 (42%) 
18 (35%) 
12 (23%) 
Surgical procedure 
    wide local excision 
    mastectomy 
 
46 
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52 
0 
Time from surgery to radiotherapy (days) 60 (16) 62 (14) 
Electron breast boost  [10Gy/5#/1 week] 1 1 
SCF irradiation  [40Gy/15#/3 weeks] 2 1 
(BMI = body mass index; HADS = hospital anxiety and depression scale; IPAQ = international 
physical activity questionnaire; HRT = hormone replacement therapy; TNM = tumour, node, 
metastases; SCF = supraclavicular fossa) 
 
Liver dose-volume data is summarised in Table 2. Percentage liver volumes were imputed for 
four right-sided and six left-sided cases. The minimum liver dose for both left- and right-
sided treatments was zero cm3 at all dose levels. The lowest maximum liver dose was 0.5% 
and 1% of the reference dose for left- and right-sided, respectively. 
 
Table 2 Liver dose-volume data for irradiation of left- and right-sided tumours 
Dose 
level 
Liver variable      Maximum Mean (SD) Median (IQR) 
Left Right Left Right Left Right 
10% 
V10absolute (cm3) 72 226 1.5 (10.4) 56.3 (52.8) 0 40.5 (61) 
V10relative (%) 4.1 18.7 0.9 (0.6) 4.5 (3.8) 0 3.7 (4.9) 
50% 
V50absolute (cm3) 21 92 0.4 (3.0) 22.1 (22) 0 16 (29) 
V50relative (%) 1.3 7.9 0 (0.1) 1.7 (1.5) 0 1.2 (2.2) 
90% 
V90absolute (cm3) 13 62 0.3 (1.8) 11.3 (14.3) 0 5 (18.2) 
V90relative (%) 0.5 5.0 0 (0.1) 0.9 (1.1) 0 0.5 (1.4) 
 Max dose (%) 101.3 113.1 7 (14.4) 87.1 (32) 4.5 (3.3) 101.6 (17.3) 
 
As the liver dose-data was positively skewed, median values were more informative. 
Frequency of median doses, and a maximum liver dose of 4.5% (IQR 3–6.3), indicated liver 
irradiation was negligible for all but three left-sided treatments. Therefore, statistical tests 
were conducted on right-sided treatments only.  
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Spearman’s rank test for right-sided treatments showed the breast size proxy Vbreast95 
correlated strongly with liver irradiation: Vliver 10 ρ = .8, p<0.0001; Vliver50 ρ = .7, p<0.0001; 
Vliver90 ρ = 0.6, p<0.0001; max liver dose ρ = 0.3, p = 0.01. Significance levels remained when 
controlling for BMI. 
Correlations between liver dose-volume variables and longitudinal sIL-6R and mean 
corpuscular volume (MCV) are summarised in Table 3. Mean corpuscular haemoglobin 
concentration returned similar results to those for MCV, but all other blood counts were 
statistically non-significant. Sample size is n = 52, except four weeks post-treatment data was 
n = 49 as three right-sided patients declined to return for blood sampling.  
Table 3 Mean (SD) interleukin-6 soluble receptor (sIL-6R) and mean corpuscular volume 
(MCV) values and longitudinal correlations with liver dose-volume parameters  
 Before RT  +10 fractions  +15 fractions  +4 weeks post-RT 
 sIL-6R (ng/dL) 
 38.9 (11.7)  40.1 (10.2)  43.5 (12.2)  38.6 (11.5) 
Liver  ρ (p)  ρ (p)  ρ (p)  ρ (p) 
V10 (cm3) .15 (0.2)  .29 (0.03)*  .33 (0.01)**  .40 (0.007)** 
V50 (cm3) .16 (0.16)  .26 (0.06)  .26 (0.06)  .36 (0.01)** 
V90 (cm3) .17 (0.16)  .21 (0.13)  .22 (0.11)  .33 (0.02)* 
Max dose (%) -.07 (0.63)  -.13 (0.93)  -.03 (0.98)  .04 (0.80) 
 
 MCV (fL) 
 91.8 (4.3) 92.7 (4.2)  92.7 (4.4) 90.8 (6.7) 
Liver ρ (p)  ρ (p)  ρ (p)  ρ (p) 
V10 (cm3)  -.24 (0.08)  -.28 (0.04)*  -.28 (0.04)*  -.32 (0.02)* 
V50 (cm3) -.35 (0.01)**  -.36 (0.009)**  -.36 (0.009)**  -.40 (0.005)** 
V90 (cm3) -.30 (0.03)*  -.34 (0.01)**  -.31 (0.02)*  -.39 (0.01)** 
Max dose (%) -.10 (0.48)  -.08 (0.56)  -.17 (0.23)  -.18 (0.22) 
(Vx = volume of liver within the x isodose level; RT = radiotherapy; * sig at <0.05; ** sig at < 0.01) 
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After adjusting for age, smoking pack years, depression and physical activity, a significant 
association remained between Vliver10 and sIL-6R concentration at four weeks post 
radiotherapy (beta = 0.38, p = 0.01). When BMI was added to the regression model the 
association was no longer statistically significant (beta = 0.30, p = 0.07). This is probably due 
to the significant correlation between these two variables (r = 0.5, p< 0.0005). 
A one-way ANOVA explored a theoretical impact of BMI on baseline MCV. BMI was 
collapsed into tertiles approximating to WHO categories for low (< 25 kg/m2), pre-obese 
(25–29.9 kg/m2) and obese (≥ 30 kg/m2). There was no statistically significant difference in 
MCV for the three groups (F = .32, p = 0.73). 
 
Discussion  
Up to 226cm3, 92cm3 and 62cm3 of the liver was irradiated to at least 10%, 50% and 90% of 
the prescription dose during free-breathing local radiotherapy. This equates to about 19%, 
8% and 5% of the liver irradiated within the respective isodose. Such doses were atypical, 
with the median point estimate being 1.2% (interquartile range 0.3 to 2.5%) of the liver 
irradiated within the 50% isodose for participants with right-sided tumours.  
It has long been assumed that liver exposure during breast radiotherapy is clinically 
insignificant. Population-level data indicate that patients with breast cancer have a small but 
existing risk of developing a second primary liver tumour after treatment, inferred largely to 
relate to genetic and lifestyle factors.20,21 Santos et al. estimate a lifetime attributed risk of 
approximately 20 hepatic malignancies per 10,000 patient years across a range of modern 
radiotherapy techniques.7 Radiation-induced cases are difficult to isolate in the absence of 
linked patient data8 and reliance on anthropomorphic phantom dosimetry.20 The current 
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dose-volume data, established on real anatomy/plans, suggests that liver dose is negligible 
for approximately 70% of patients. However, a wide range of liver dose was evident: the 
likelihood of a substantial volume of liver being located within the high-dose region 
increasing significantly with breast size. This relationship was probably due to field borders 
extending to cover pendulous breasts falling more inferiorly under gravity and an angled 
breastboard.22 Where a significant volume of liver irradiation is apparent at treatment 
simulation, with breast size being a good indicator, right-sided DIBH provides a feasible 
approach to flatten the diaphragm and displace the liver inferiorly.  
DIBH has previously demonstrated reduced liver volume within the 50% isodose by a mean 
of 42.3 cm3 (range 0–179cm3) for the use of ‘wide tangents’ localised to treat the internal 
mammary chain (IMC).23 Recent review evidence supports IMC irradiation for medially 
placed axillary node-positive disease.24 In this setting, there is a relative indication for the 
reduction of lung and potentially liver doses through right-sided DIBH. The upper range of 
liver exposure evident in the current participants could also be minimised for standard local 
breast tangents.10 Leveraging the inherent stability of DIBH can reduce cranio-caudal 
intrafraction hepatic motion from 19mm to 1–5mm,25,26  reduce liver volume by 63% 
(134cm3 to 50cm3) and mean liver dose by 46% (from 4.8 to 2.6 Gy) compared to a free 
breathing plan10 and deliver superior ipsilateral and total lung dosimetry.27,28 
The range of maximum liver dose in the current study was surprisingly large for left-sided 
treatments. Median data confirmed the phenomena of liver irradiation was negligible for all 
but one participant, who had a medially-placed tumour, a high BMI and SCF irradiation that 
exaggerated inferior beam divergence for tangential fields. Routine adoption of mono-
11 
 
isocentric field matching and left-sided DIBH are both likely to have additional benefits of 
reducing liver irradiation for such unusual cases.  
Evaluating clinical significance 
Classic radiation induced liver disease (RILD) would be extremely unlikely considering the 
dose-volume data established in this study.29 Modest, statistically significant, positive 
correlations were evident between the volume of liver within the 10% isodose and 
circulating sIL-6R concentration during and after, but not before treatment. The pattern of 
data is consistent with a systemically discernible low-dose effect for right-sided treatments. 
The finding is best considered hypothesis generating, but suggests that radiation-induced 
shedding of sIL-6R could theoretically contribute to adverse inflammatory states and poorer 
outcomes.30,31. Murine studies have shown hepatocytes to be a main source of systemic sIL-
6R and that dysregulation of the IL6/sIL-6R complex plays a role in impairing the ability of 
the liver to regenerate after injury.32-34 IL-6 and sIL-6R are negative prognostic markers for 
breast cancer proliferation, resistance and metastasis.35-37 At a behavioural level, elevated 
sIL-6R has been associated with fatigue, depression and poor sleep hygiene in breast cancer 
populations.38-40  
A negative association between liver irradiation and MCV was evident in the current data, 
before, during and after radiotherapy. The consistency of associations and lack of 
association with other blood counts indicate a modest statistically significant result, of 
unknown clinical significance. Maximum liver dose was neither a useful predictor of sIL-6R 
concentration nor blood counts. 
22  
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The study design enabled original longitudinal data, but did not link dosimetry to clinical 
outcomes. Further studies could test the hypothesis that technical approaches can virtually 
eliminate the volume of liver tissue within the high-dose region and thereby minimise low-
dose induction of sIL-6R and associated behavioural effects. Alternative free-breathing 
techniques with potential to reduce mean liver doses include proton therapy, partial breast 
irradiation, segmented intensity modulated radiotherapy and two-arc volumetric therapy.41 
This is important as the liver broadly functions as a parallel organ that is susceptible to 
damage from lower doses spread across a larger volume.42 The exclusion of 
prior/concomitant systemic anti-cancer therapies helped to isolate the biological effects of 
radiation, but reduces generalisability to the wider population. The liver plays a central role 
in the metabolism of pharmacological agents. Tamoxifen, Lapatinib and other agents used in 
modern breast cancer protocols share a hepatotoxic profile.16,43,44 The liver tolerance is also 
reduced by hypofractionated doses,16 as prescribed to study participants.  
Conclusions 
Up to 8% of the liver is irradiated within the primary beam during contemporary local right-
sided breast radiotherapy. Where treatment planning images demonstrate substantial liver 
exposure, right-sided DIBH provides a simple way to ensure the liver dose, the consequent 
risk of acute and chronic inflammatory toxicity and second primary liver cancer is as low as 
reasonably practicable; especially during IMC irradiation and extreme hypofractionation or 
for women with large/pendulous breasts or liver function is compromised.  
List of abbreviations 
BMI: Body mass index; CTV: Clinical target volume; DIBH: Deep inspiration breath-hold; Gy: Gray; HADS: 
Hospital anxiety and depression scale; HRT: Hormone replacement therapy; IL-6: Interleukin-6; IPAQ: 
International physical activity questionnaire; IQR: Inter-quartile range; MCV: Mean corpuscular volume; NHS: 
National Health Service; PTV: Planning target volume; SCF: Supraclavicular fossa; sIL-6R: Interleukin-6 soluble 
receptor; TNM: Tumour, node, metastases; Vliverx: Volume of liver irradiated within x% isodose 
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